Trials / Completed
CompletedNCT01310972
Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX
Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 6 (actual)
- Sponsor
- King Faisal Specialist Hospital & Research Center · Academic / Other
- Sex
- All
- Age
- 14 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX
Detailed description
It's a study of adjuvant colon carcinoma using ELOXatin/5-FU based chemotherapeutic regimen called ACCELOX as a definitive curative therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Registry | Registry |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2011-03-09
- Last updated
- 2018-08-10
Locations
1 site across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT01310972. Inclusion in this directory is not an endorsement.